[HTML][HTML] Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - Reviews in Endocrine …, 2021 - Springer
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone-from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, M Adorni, C Sirtori… - … IN ENDOCRINE AND …, 2021 - air.unipr.it
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
G Baris, M Bonomi, MP Adorni… - … in Endocrine & …, 2021 - search.proquest.com
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - Reviews in Endocrine …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The cardiovascular (CV) benefit and safety of
treating low testosterone conditions is a matter of debate. Although testosterone deficiency …
treating low testosterone conditions is a matter of debate. Although testosterone deficiency …
[PDF][PDF] Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni… - Reviews in …, 2021 - access.archive-ouverte.unige.ch
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
[HTML][HTML] Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - Reviews in Endocrine …, 2021 - ncbi.nlm.nih.gov
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone-from subclinical atherosclerosis to lipoprotein function to heart failure.
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - Reviews in Endocrine …, 2021 - europepmc.org
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone-from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni… - … in endocrine & …, 2021 - pubmed.ncbi.nlm.nih.gov
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - … IN ENDOCRINE & …, 2021 - air.unimi.it
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosteronedeficiency has been linked to a rise in major adverse CV …
of debate. Although testosteronedeficiency has been linked to a rise in major adverse CV …
[PDF][PDF] Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure
B Gencer, M Bonomi, MP Adorni, CR Sirtori… - Reviews in Endocrine …, 2021 - air.unimi.it
The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …
of debate. Although testosterone deficiency has been linked to a rise in major adverse CV …